SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the ...
In a high-fat diet-induced model of humanized INHBE obese mouse (hINHBE DIO mouse), CMS-D008 significantly reduced hepatic INHBE mRNA expression and serum Activin E protein levels, leading to marked ...
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected to present Phase II updated results for BW-20805 at the ...
Title: “Onvuzosiran Provides Deep and Sustained Reduction of Plasma Kallikrein Levels for the Treatment of HAE” (Abstract number: 100399) Session: Flash Talks session (L-FT04) entitled Immune ...
Alnylam has partnered with the person who helped put the “T” in ChatGPT, paying $30 million to work with Jakob Uszkoreit’s ...
The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...
Under the terms of the agreement, Alnylam will provide $30 million in upfront consideration, including cash and an equity ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has generated over a dozen FDA-approved therapeutics and drugs in late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results